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Negative symptoms are currently viewed as having a 2-dimensional structure, with factors reflecting 
diminished expression (EXP) and motivation and pleasure (MAP). However, several factor-analytic 
studies suggest that the consensus around a 2-dimensional model is premature. The current study 
investigated and cross-culturally validated the factorial structure of BNSS-rated negative symptoms 
across a range of cultures and languages. 
Method 
Participants included individuals diagnosed with a psychotic disorder who had been rated on the Brief 
Negative Symptom Scale (BNSS) from 5 cross-cultural samples, with a total N = 1691. First, 
exploratory factor analysis was used to extract up to 6 factors from the data. Next, confirmatory factor 
analysis evaluated the fit of 5 models: (1) a 1-factor model, 2) a 2-factor model with factors of MAP 
and EXP, 3) a 3-factor model with inner world, external, and alogia factors; 4) a 5-factor model with 
separate factors for blunted affect, alogia, anhedonia, avolition, and asociality, and 5) a hierarchical 
model with 2 second-order factors reflecting EXP and MAP, as well as 5 first-order factors reflecting 
the 5 aforementioned domains. 
Results 
Models with 4 factors or less were mediocre fits to the data. The 5-factor, 6-factor, and the hierarchical 
second-order 5-factor models provided excellent fit with an edge to the 5-factor model. The 5-factor 
structure demonstrated invariance across study samples. 
Conclusions 
Findings support the validity of the 5-factor structure of BNSS-rated negative symptoms across 
diverse cultures and languages. These findings have important implications for the diagnosis, 
assessment, and treatment of negative symptoms. 
 
Introduction 
Early factor-analytic studies indicated that negative symptoms are a domain of psychopathology that 
is distinct from psychosis and disorganization in individuals with schizophrenia.1–3 These studies 
relied on broad-bandwidth rating scales such as the full Positive and Negative Syndrome Scale 
(PANSS) and the Brief Psychiatric Rating Scale (BPRS) that assess negative symptoms along with 
other symptoms of schizophrenia. However, the use of broad-bandwidth measures to adjudge the 
factor structure of negative symptoms is flawed because covariance patterns in the symptom data 
cause negative symptom items to aggregate together, making the construct arbitrarily unidimensional. 
Factor analyses evaluating the structure of negative symptoms with narrow-bandwidth scales—ie, 
measures of negative symptoms alone, with no items included from other constructs—suggest that 
the structure of negative symptoms is multidimensional.4 A 2-factor solution has commonly been 
reported for a range of narrow-bandwidth measures, including the Scale for the Assessment of 
Negative Symptoms (SANS), Schedule for the Deficit Syndrome (SDS), Brief Negative Symptom 
Scale (BNSS), Clinical Assessment Interview for Negative Symptoms (CAINS), and negative 
symptom items of the PANSS.5–15 The 2 dimensions reflect: (1) diminished expressivity (EXP), 
consisting of alogia and blunted affect items and (2) motivation and pleasure (MAP), consisting of 
avolition, asociality, and anhedonia.5–12 These findings have led the field to widely accept the 2-
dimensional structure of negative symptoms.4 This 2-dimensional model has been very influential, 
impacting important decisions, such as how negative symptoms are described in the DSM-5, how 
treatment targets are defined, how scales are scored for statistical analysis, and how studies search 
for pathophysiological mechanisms.13 
However, the 2-dimensional conceptualization of negative symptoms may be statistically or 
theoretically insufficient. Support for the 2-dimensional structure comes from studies using 
exploratory factor analysis (EFA), a data reduction method that infers the presence of latent factors 
responsible for shared variance among items in a scale.14,15 EFA is limited in that it does not specify 
an underlying structure of negative symptoms, but rather assumes that each item in a scale could be 
related to each underlying latent factor.15 Prior EFA studies were important for generating hypothesis 
about dimensions in negative symptoms. They are not, however, actual tests of the validity of a 2-
factor structure and their exploratory nature does not allow direct assessment of their factorial validity 
relative to competing factor models of negative symptoms.13 Moreover, Garcia-Portilla and 
colleagues16 using EFA concluded that a 3-factor structure that distinguished inner-world experiences 
(ie, avolition and blunted affect) from external features (anhedonia and asociality), and alogia was 
preferable to a 2-factor model. The 3-factor model has yet to be replicated, but it shows that the 
consensus that 2 factors best describe the multidimensionality of negative symptoms is premature. 
Confirmatory factor analysis (CFA) is required to test competing models and evaluate the 
dimensional structure of BNSS-rated negative symptoms. Published CFA studies have examined the 
SANS, and were problematic because they included items not part of the negative symptom construct, 
which limits conclusions that can be drawn.17,18 Axelrod and colleagues19,20 conducted 2 early CFA 
studies of negative symptoms measured with the Negative Symptom Assessment (NSA). In the first 
study of a 26-item NSA, they found that a multidimensional model that included communication, 
emotion/affect, social involvement, motivation, retardation, and gross cognition as 6 separable factors 
best described negative symptoms. In the second study, they used a 16-item version of the measure 
which now excluded items that originally loaded onto the “gross cognition” factor. The authors 
replicated 5 of the original factors—communication, emotion/affect, social involvement, motivation, 
and retardation. The statistical fit indices obtained in both studies favored their chosen 5 or 6-factor 
models over 1- to 4-factor solutions. Their chosen models, however, proved to be mediocre fits to the 
data based on statistical fit indices. Further, both 26- and 16-item versions of the NSA did not include 
items that assess anhedonia. 
The 2005 NIMH-MATRICS consensus conference on negative symptoms sought to establish the 
scope of negative symptoms to advance the development of evidence-based measures and 
treatments.21 The conference identified affective flattening, alogia, asociality, avolition, and 
anhedonia as domains of negative symptoms. These domains subsequently informed the content 
coverage of the BNSS and the CAINS. Strauss et al (Unpublished data) conducted CFA of 3 current 
negative symptoms scales, the BNSS (n = 192), CAINS (n = 400), and SANS (n = 268). The study 
found that with all 3 measures, a 5-factor model consistent with the NIMH-MATRICS domains and 
a hierarchical 5-factor model with MAP and EXP as second-order factors that influence the 5 factors 
provided excellent fit and outperformed other factor models. These findings suggest that the recent 
trend toward conceptualizing negative symptoms in relation to the MAP and EXP does not capture 
the complexity of negative symptoms. 
The current study attempted to determine the correct factorial structure of BNSS-rated negative 
symptoms using data obtained across a range of cultures and languages. The study took both an 
empirical exploratory (EFA) and a model-based (CFA) approach to determining the correct factor 
structure. A model-based approach allowed (1) a comparison of the NIMH consensus 5-factor model 
with alternate models including—the unidimensional/1-factor model, MAP/EXP 2-factor, Garcia-
Portilla et al.’s 3-factor model, and the hierarchical 5-factor model; and (2) testing the cross-cultural 
measurement invariance of the correct factor structure using data from 5 samples including N = 1691 
participants from Italy, Spain, China, Switzerland, and the United States. The EFA extracting 1–6 
factors from the data allowed (1) an examination of the relative viability of several factor models (eg, 
4-factor and 6-factor models) in the absence of guiding theory or a priori evidence; (2) searching for 
converging evidence of the preferred factor structure from CFA and EFA; (3) an assessment of the 
preferential loading of BNSS items; and (4) in the absence of guiding theory the loading preference 
of item 4 “Lack of Normal Distress” in fitted factor models. Although not adjudged as a negative 
symptom in the 2005 NIMH-MATRICS conference, item 4 “Lack of Normal Distress” was included 
in the BNSS because of its association with reduced emotional expression and deficit symptoms. In 
previous studies, item 4 loads with BNSS factors albeit with lower saturation than other items.11 EFA 
was used to adjudicate the correct factor location of this item. It was predicted that EFA and CFA 
will demonstrate preference for a 5-factor model of BNSS-rated negative symptoms over alternate 
models. In concert with Strauss et al (Unpublished data), the 5-factor and hierarchical models were 
expected to provide excellent fit to the data, with the 5-factor model producing the best fit. It was 
further predicted that the preferred factor structure would be cross-culturally invariant and produce 
strong fits in multinational cross-validation samples. 
Methods 
Participants 
The data sets used to investigate the factorial structure of negative symptoms in the current study 
were drawn from several international investigations of the psychometric properties of the BNSS and 
its clinical utility. These included samples obtained from collaborations in Italy (n = 937), Spain (n = 
115), China (n = 163), and Switzerland (n = 119) that used versions of the BNSS formally translated 
into Italian, Spanish, Chinese (simplified script), and German, respectively.22–25 The study also 
included a USA-based sample (n = 357) obtained with the original English version.11Additional 
sample details are provided in the supplementary material. Table 1summarizes the demographic 
characteristics and clinical composition of the study samples. Participants from Italy, Spain, and the 
United States were evaluated to ensure that they met Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) criteria for schizophrenia or schizoaffective disorder using the Structured 
Clinical Interview for DSM-IV (SCID). Swiss participants were adjudged as meeting DSM diagnostic 
criteria using the Mini-International Neuropsychiatric Interview (MINI). Participants from China 
were assessed with the International Classification of Diseases and Related Health Problems, Tenth 
Revision (ICD-10) criteria. 
 
Table 1. 
Characteristics of the Brief Negative Syndrome Scale (BNSS) Study Samples Used in the Analyses 
 
Note: ICC: intraclass correlation coefficient. Internal consistency values are Cronbach’s alpha 
estimates. When a scale has more than 5 response categories, Cronbach’s alpha produces robust 
estimates of internal consistency comparable to other methods of computing internal consistency for 
categorical outcomes such as ordinal alpha or McDonald’s alpha. 
Procedures 
Each study administered the BNSS as part of broader research aims to illuminate the phenomenology 
and treatment of negative symptoms. Given that investigators in Italy, Spain, Switzerland, and China 
administered translated versions of the BNSS, a standard method of translation served to ensure the 
equivalence of the translated versions to the original English version. First, the BNSS was forward 
translated to the target language. Next, the translated version was independently back-translated and 
forwarded to the scale authors (BK and GS), who worked with the translators to reconcile the 
translation with the original English version. 
The inter-rater reliability of the BNSS was established at each site through the use of gold-standard 
training videos and ratings of face-to-face interviews completed by the BNSS authors. All raters 
completed BNSS training using standardized training materials and received feedback from 
completing ratings on gold-standard videos. Raters in each study had at minimum, bachelors-level 
training, and/or extensive experience completing psychiatric interviews. BNSS raters in each parent 
study met minimum standards of inter-rater reliability with intraclass correlation coefficients that 
exceed 0.90 (table 1). 
Data Analysis 
The overall analytic strategy was to establish the factor structure of BNSS-rated negative symptoms 
in a calibration sample and then cross-validate the established factor structure across languages and 
cultures. Rather than test all factor models in every study sample, the decision was made to first 
estimate alternate factor models in a calibration sample and then cross-validate best fit models to: (1) 
decrease the number of separate factor models that would need to be estimated; and (2) decrease the 
likelihood that models with apparent fit in one sample but had capitalized on chance (type I error) are 
interpreted. The calibration sample included 566 cases (60.4%) drawn randomly from the largest 
study sample, the Italian dataset. The remaining 371 cases in the Italian dataset were designated as 1 
of the 5 cross-validation samples; therefore, each language and data source served in the cross-
validation of the preferred factor structure. 
To examine the fits of evaluated models, BNSS ratings were factor analyzed with model estimation 
methods that are robust to distributional non-normality in BNSS ratings. EFA models ranging from 
1 to 6 classes were estimated first excluding and then including item 4 “Lack of Normal Distress” to 
identify the item’s preferred factor location. EFAs were completed with the oblique Quartimin 
rotation. Unlike previous EFA studies, the preferred factor structure was adjudged by examining 
pattern loadings and objective fit indices (discussed below). Next, CFA was used to test competing 
hypotheses about the factor structure of negative symptoms. Five models estimated included a 
unidimensional/1-factor, MAP/EXP 2-factor, Garcia-Portilla et al’s 3-factor, the NIMH consensus 5-
factor, and the hierarchical 5-factor models. Items included on each factor within the 5 models are 
presented in table 2. The estimators were the weighted least squared estimator with standard errors 
and mean-and variance adjusted chi-square test (χ2) that use a full-weight matrix (WLSMV), and the 
maximum likelihood with robust standard errors (MLR). All model estimations were carried out in 
Mplus Version 5.0.26 Model modification indices were obtained to assess and evaluate all fixed 
parameters (eg, specified loading patterns) to determine which fixed parameters if freely estimated 
would have improved the model being evaluated. By convention, modification indices are used jointly 
with theory to guide attempts to re-specify poor fitting models. 
Table 2. 
Confirmatory Factor Analysis Models of the Brief Negative Symptom Scale (BNSS) 
 
 
Several indices served to evaluate the goodness-of-fit of estimated factor models.27–33These include 
the χ2 test, the root-mean-square error of approximation (RMSEA), the comparative fit index (CFI), 
the Tucker–Lewis index (TLI), the standardized root mean squared residual (SRMR), and the 
weighted root mean squared residual (WRMR), all of which help to access the absolute fit. 
Information criteria including Akaike information criteria (AIC), Bayesian information criteria (BIC), 
and the sample-size adjusted BIC (aBIC) are used for comparing the relative fits of alternate models. 
Models with lower values are preferred. RMSEA values of 0.08 and lower are considered adequate 
fit. CFI and TLI values of 0.95 and higher are considered indicative of strong fitting models. SRMR 
values range from 0 to 1 with values of 0.08 or lower indicative of good fitting models. WRMR values 
of about 1.00 and lower are considered strong fits. Additional details of fit indices are provided in 
the supplementary material. 
Multi-group CFA was used to assess the measurement invariance of the BNSS-preferred factor 
structure across the multi-national samples. This comprised tests of configural, metric, scalar, and 
residual invariance that are conducted sequentially.34,35 Configural invariance requires that items load 
on the same factor across subsamples. Metric invariance requires that factor loadings be equivalent 
across the multi-national samples. Scalar invariance requires that both factor loadings and intercepts 
are equivalent across study samples. Residual factorial invariance adds an additional constraint 
requiring that residual variances are equal across samples. Changes in chi-square (χ2 diff), CFI, TLI, 
and RMSEA estimates as constraints were imposed on the model were used to evaluate the invariance 
models. CFI change has the most empirical support and values not exceeding 0.01 provide evidence 
that constraints imposed on model are tenable.34–36 
Results 
The study aims were addressed in 3 stages. First, EFA was used to extract up to 6 factors from the 
BNSS using the calibration sample. Two sets of EFAs were completed at this stage—BNSS ratings 
first excluding, and then including item 4 “Lack of Normal Distress.” Next, model-based CFAs were 
used to compare the relative fits of the 1-, 2-, 3-, 5-factor, and hierarchical models in the calibration 
sample. The favored factor models were tested in each of the 5 cross-validation samples. Finally, 
measurement invariance of the preferred factor structure across study samples was sequentially 
evaluated for metric, scalar, and residual invariance. 
Table 1 summarizes the characteristics of the study samples. Cronbach’s alpha exceeded 0.90 in every 
study sample, suggesting that raters were able to reliable assess negative symptoms with the BNSS 
regardless of the language of administration or participants’ country of origin. Save for one participant 
in the Italian sample who was subsequently excluded from the analysis due to missing data, complete 
ratings were obtained for all BNSS items in all of the study samples. The variability in BNSS total 
score across samples likely reflects the illness acuity of participants recruited in the particular parent 
study. 
EFA of the BNSS Calibration Sample 
The results of EFA runs in the calibration sample are summarized in table 3. Although CFI and TLI 
estimates were acceptable for 1 through 4-factor models, high RMSEA estimates suggested that these 
were mediocre fits to the data. With or without item 4, the EFA 5-factor and 6-factor models were 
strong fits to the data with CFI, TLI, RMSEA, and SRMR that fell in the excellent-fit range. Without 
item 4, the AIC and other information criteria favored a 5-factor model over the 6-factor model. 
Moreover, the 6-factor solution produced 2 factors with single items. 
Table 3. 
Model Fit Results of the Exploratory Factor Analysis of BNSS Items 
 
 
Note: LL, loglikelihood; k, number of free parameters; AIC, Akaike information criterion; BIC, 
Bayesian information criterion; aBIC, sample size adjusted BIC; CFI, comparative fit index; TLI, 
Tucker–Lewis index; RMSEA, root mean square error of approximation; SRMR, standardized root 
mean square residual; WRMR = weighted root mean square residual. The preferred factor models are 
presented in bold. Both weighted least square (WLSMV) and maximum likelihood (MLR) estimators 
were used in the analyses. Chi-square for the baseline EFA model with item 4 excluded: χ2 (66) = 
190846.57, P < .0001. Chi-square for the baseline EFA model with item 4 included: χ2 (78) = 
194394.78, P < .0001. 
 
With item 4 included in the model, the information criteria slightly preferred the 6-factor solution. 
Subsequent examination of the matrix of rotated loadings of the 6-factor solution showed that all 
BNSS items including item 4 weakly loaded on the sixth factor with all loading coefficients less than 
an absolute value of 0.11. This suggests that a sixth factor contributes little to explaining the pattern 
of covariances of BNSS items and the 6-factor solution should be rejected in favor of the more 
parsimonious 5-factor model. 
The rotated 5-factor matrices for all factor solutions are presented in supplementary tables S1–S12. 
Item 4 cross-loaded onto 2 BNSS factors—anhedonia and asociality. 
CFA of the BNSS-Rated Negative Symptoms in the Calibration Sample 
The results of the CFAs conducted in the calibration sample are summarized in table 4. All CFA 
models excluded item 4 given that it was not a recognized negative symptom in the NIMH-MATRICS 
conference. The 1-factor, 2-factor, and the 3-factor models proved to be mediocre fits to the data. The 
1-factor models were a poor fit due to mediocre CFI, RMSEA, and WRMR values. Although the CFI 
and the TLI for the 2-factor and 3-factor models exceeded the 0.95 threshold, both were poor fits to 
the data based on high RMSEA and WRMR values. 
Table 4. 
Confirmatory Factor Analysis of BNSS Items: Model Fit Results 
 
 
Note: LL, loglikelihood; k, number of free parameters; AIC, Akaike information criterion; BIC, 
Bayesian information criterion; aBIC, sample size adjusted BIC; CFI, Comparative fit index; TLI, 
Tucker–Lewis index; RMSEA, root mean square error of approximation; WRMR, weighted root 
mean square residual. Preferred factor structures in the calibration sample based on fit indices are 
presented in bold font. Chi-square for the baseline model: χ2 (5) = 14458.07, P < .001 (item 4 
excluded). Both weighted least square (WLSMV) and maximum likelihood (MLR) estimators were 
used in the analyses. Monte Carlo-based numerical integration was used in the estimation of models 
to ease computation time. The number of Monte Carlo generated integration points ranged from 5000 
to 6000. Chi-square for the baseline model in the Italian sample: χ2 (5) = 9279.67, P < .001. Chi-
square for the baseline model in the American sample: χ2 (9) = 7885.97, P < .001. Chi-square for the 
baseline model in the Spanish sample: χ2 (7) = 2531.37, P < .001. Chi-square for the baseline model 
in the Swiss sample: χ2 (8) = 4029.90, P < .001. Chi-square for the baseline model in the Chinese 
sample: χ2 (6) = 2760.20, P < .001. 
 
The 5-factor and the hierarchical models produced CFI and TLI values that suggest strong fit to the 
data. The RMSEA values for both factor models just fell under the 0.08 threshold, suggesting 
adequate fits to the data. Both the 5-factor and hierarchical models also produced WRMR estimates 
that fell below 1.00, suggesting strong fits to the data. 
The AIC and other information criteria favored the 5-factor model and the hierarchical model over 
the 1-, 2-, and 3-factor models. The information criteria slightly favored the 5-factor model over the 
hierarchical model. 
Cross-validation in Multi-National Samples 
Given their strong performance in the calibration sample, we tested both the 5-factor and hierarchical 
models in cross-validation samples. Table 4 summarizes the results of cross-validating the BNSS 5-
factor and the hierarchical models. Both factor models proved to be strong fits to the data based on 
CFI and TLI estimates that far exceeded the 0.95 threshold in each sample. Across samples, the 
RMSEAs frequently fell below the 0.08 threshold that would suggest an adequate fit. The exceptions 
were the 5-factor models in the Chinese and American sample and the hierarchical model in the 
Chinese sample. Like the CFI and TLI however, the WRMR suggested strong fits for both models in 
all samples. 
The AIC and other information criteria produced values that were lower for the 5-factor model than 
the hierarchical model in all of the samples. This suggests that although both the 5-factor and 
hierarchical models are cross-culturally valid, the 5-factor model is slightly stronger. Supplementary 
table S13 includes internal consistency estimates of the 5 factors for each of the study samples. 
Assessment of Measurement Invariance Across Samples 
We conducted tests of factorial invariance among the 5 multinational samples using the 5-factor 
model. The analysis was completed on the full study sample. Due to the unequal group sizes, which 
may bias estimates in favor of the larger Italian and USA-based samples, the analysis was also 
completed in a subsample of 575 individuals with 115 individuals from each subsample. To this end, 
115 individuals were randomly drawn from the Italian, Chinese, Swiss, and American samples, 
whereas the entire Spanish sample was included. The results were not remarkably different. Table 
5summarizes all the fit indices of the measurement invariance model. Fit values from the configural 
model showed that the 5-factor model held across all samples with CFI and TLI that exceed 0.99 and 
RMSEA falling below the 0.08 threshold. Metric invariance (equivalence of factor loadings) was 
similarly supported with CFI and TLI that exceed 0.99 and RMSEA close to 0.08. Scalar (equivalence 
of factor loading and intercepts) and residual (equivalence of loadings, intercepts, and factor residual 
variances) invariance was supported by high CFI and TLI values that decreased by less than 0.01 
from the configural and metric models. The RMSEA value suggested a slight loss of absolute model 
fit however when assumptions of scalar invariance are violated. Using modification indices, it was 
determined that item 2 in the Italian sample had a higher intercept than in the other samples. When 
item 2 was freely estimated in the multigroup CFA, the RMSEA for scalar invariance model improves 
(CFI = 0.989, TLI = 0.998, RMSEA = 0.082). This suggests that Italian participants (all outpatients) 
tended to be rated as more impaired on item 2 “Frequency of Pleasurable Activities” compared to 
participants in other samples, particularly the Chinese sample (inpatients/outpatients). 
Table 5. 
Goodness-of-Fit Indices for the Invariance Testing of the BNSS 5-Factor Structure 
 
 
Note: N = 1691. CFI, comparative fit index; TLI, Tucker–Lewis index; RMSEA, root mean square 
error of approximation. Chi-square for the baseline model: χ2 (32) = 44760.07, P < .0001. 
 
Discussion 
Factor analysis served to investigate latent dimensions in BNSS-rated negative symptoms obtained 
from 5 samples of different cultures and languages. In both EFA and CFA runs, the 5-factor model 
proved to be the preferred structure of BNSS-rated negative symptoms. The hierarchical second-order 
5-factor model also provided excellent fit, similarly supporting its factorial validity. Although a 2-
factor model consistent with the MAP and EXP dimensions emerged from the EFA, this was rejected 
on the basis of its poor objective fit to the data. Previous studies erroneously accepted this solution 
for its parsimony and logic in the absence of objective fit indices. Evidence of factorial invariance 
across multinational samples indicated that the 5-factor loading pattern holds cross-culturally and can 
be studied across translations. The current study extends evidence of the 5-factor model of negative 
symptoms across 5 cultures and languages using translated or original English versions of the BNSS. 
There are several important implications for these findings. First, the 5-factor structure is not 
culturally bound. This suggests that these 5 domains reflect core processes inherent to the diagnosis 
that are not dependent on language or cultural influences. Second, these results also demonstrate that 
not only are early views of negative symptoms as a single construct inaccurate, but the current trend 
toward viewing negative symptoms as a 2-dimensional construct is also not fully justified. Rather, 
negative symptoms are best conceptualized in relation to the 5 negative symptom domains identified 
in the 2005 NIMH consensus conference: anhedonia, avolition, asociality, alogia, and blunted 
affect.21 The 2-dimensional conceptualization has had an important, but statistically unjustified 
influence on the field. For example, the DSM-5 describes negative symptoms in relation to the broad 
MAP and EXP dimensions, rather than the 5 consensus domains. This procedure may lead to 
underspecified diagnoses that do not capture the granularity of the construct. Future versions of the 
DSM should list and define each domain separately. Failure to do so will probably hamper efforts to 
identify the psychological and pathophysiological mechanisms of each domain. Treatments may also 
have differential efficacy for these 5 domains, and failing to evaluate the 5 domains separately may 
prevent observation of meaningful treatment effects that are domain-specific, rather than tied to the 
2 broader dimensions. Treatment development efforts will be advanced by pharmacological and 
psychological treatments targeted to specific factors. Clinical trials testing such treatments should 
specify which of the 5 factors represent the primary target(s)/outcome(s). 
The NIMH RDoC initiative provides a framework for exploring neurobiological processes associated 
with aspects of “positive valence systems” and “social processes” that map onto these 5 clinical 
domains.37,38 Some of these pathophysiological processes may be broadly related to the MAP and 
EXP dimensions, whereas others may be tied to 1 of the 5 domains more specifically. Future 
investigations are needed to explore pathophysiology tied to each domain to promote targeted 
treatment development. Such trials should focus on one of the domains specifically. It is possible that 
trials already conducted have observed treatment effects, but these were masked by procedures for 
calculating overly broad scores. Reanalysis of large past studies with appropriate instruments may be 
warranted, and interpretation of future treatment trials would be strengthened by calculating scores 
for each of the 5 domains, rather than a global total score, or MAP and EXP dimensional scores, 
alone. 
Strauss et al (Unpublished data) demonstrated that other measures besides the BNSS—the SANS and 
the CAINS—similarly captured the 5 domains. Developers of future negative symptom scales should 
endeavor to generate candidate items that capture each of these 5 domains. This will support a more 
focused creation of items for initial review and psychometric testing. It will also ensure that rating 
scales are brief yet comprehensive in their coverage of negative symptoms. The factorial validity of 
the hierarchical model also has implications for scale development. The MAP and EXP second-order 
factors represent higher-order broad dimensions that subsume the lower-order, narrow 5 domains. 
Measures like the BNSS and the CAINS that capture both narrow and broader facets of negative 
symptoms are potentially more comprehensive in their scope and maintain the relative advantages of 
capturing both broad and narrow facets of negative symptoms. Such measures have potentially better 
reliability and fidelity given that more items assess the broader, higher-order dimensions, and the 
narrow bandwidth domains within broad dimensions are inter-correlated.39 These measures also 
maintain the relative advantages of narrow bandwidth assessments including: (1) severity ratings and 
differences on specific domains are captured; (2) the specific effects of narrow-band domains within 
broader dimensions on external variables can be captured when the same effects may be attenuated 
in broader dimensions; and (3) better interpretability when specific narrow facets are linked to 
external variables.39,40 
The use of a multinational sample to cross-validate the 5-factor and hierarchical 5-factor models lends 
strong credence to conclusions about the factorial structure of negative symptoms. The results suggest 
that the 5-factor model is unbounded by culture, language, or setting. It represents rather a structure 
of negative symptoms that is pervasive, universal, and likely linked to distinct psychological and/or 
pathophysiological processes found across cultures. The strong cross-validation results provide 
additional evidence of the excellent psychometric characteristics of the translated versions of the 
measure. Practically, these findings suggest that the 5 factors are domains that exist globally and are 
assessable in different languages with good reliability and validity. Observed differences in the 
intercepts of item 2 is informative rather than prohibitive of the use of the BNSS cross-culturally. It 
may suggest that cultural norms impact the definition of “normal” vs “impaired” in adjudging the 
frequency of pleasurable activities. Sociocultural and contextual factors have been shown to influence 
the expression and clinical trajectory of schizophrenia symptoms.41–44 It is therefore possible that the 
frequency of pleasurable activities exhibits cultural and contextual variation that warrants further 
study. 
The current study did not evaluate the measurement invariance of the 5-factor model across other 
sources of symptom heterogeneity such as sex, diagnosis, and illness stage. These were adjudged as 
worthwhile for further validation of the 5-factor model but beyond the scope of the current study. In 
addition, the study did not examine the 5 factors in relation to the origin or form of negative 
symptoms.45,46Next is to determine if the 5-factor model is valid regardless of sex, negative symptom 
type, illness stage, or illness severity. Any determination of equivalence or nonequivalence of the 5 
domains would be informative about the phenomenology of negative symptoms. 
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Supplement to Ahmed et al.  
 
CROSS-CULTURAL VALIDATION OF THE FIVE-FACTOR STRUCTURE  
OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA 
 
 
Participants Details: The Italian sample comprised 937 individuals recruited from outpatient units, 
university psychiatric clinics, and community mental health centers that form part of the Italian 
Network for Research on Psychoses. The Spanish sample comprised 115 individuals recruited from 
three outpatient services in Oviedo and Barcelona. The Chinese sample included 163 individuals 
recruited from inpatient and outpatient settings in mainland China. The Swiss sample that was 
administered the German translation of the BNSS included 119 individuals recruited from inpatient 
and outpatient units at the Psychiatric Hospital, University of Zurich. The USA-based sample 
comprised 357 individuals recruited from outpatient clinics and community mental health programs 
affiliated with the Maryland Psychiatric Research Center (MPRC), University of Nevada Las Vegas 
(UNLV), and the State University of New York (SUNY) at Binghamton, New York. 
Fit Indices for Evaluating Factor Models: The chi-square (2) test evaluates the degree to which 
the hypothesized factor structure fits data29; however, it is sensitive to large sample sizes that may 
cause the rejection of well-fitting models. The root-mean-square error of approximation (RMSEA)30 
measures the discrepancy between the hypothesized factor model and the population covariance 
matrix when the model has unknown but optimally-chosen parameter values. RMSEA values of .08 
and lower are considered adequate fit and values .05 and lower indicate excellent fits31; however, 
the RMSEA is sensitive to model complexity and smaller sample sizes may cause RMSEA to over-
reject true population models.29 The Comparative Fit Index (CFI) and the Tucker Lewis Index (TLI) 
are incremental fit indices that compare the hypothesized factor model with the less restricted 
nested baseline model.32-33 The TLI however penalizes overly complex models. CFI and TLI values 
of .95 and higher are considered indicative of strong fitting models.29 The information criteria 
indices including Akaike Information Criteria (AIC), Bayesian Information Criteria (BIC) and the 
sample-size adjusted BIC (aBIC) are used for comparing non-nested models.34-35 Information 
criteria consider the chi-square and the model complexity in penalizing models and therefore favor 
parsimonious models. Models with lower information criteria are preferred. The Standardized Root 
Mean Squared Residual (SRMR) and the Weighted Root Mean Squared Residual (WRMR) are 
residual-based indices based on the difference of the variance-covariance matrix of the 
hypothesized model and that of the observed sample data.28,29 Both measure the average difference 
across all standardized residuals but WRMR uses a variance—weighted approach.28-29,36 SRMR 
values range from 0 to 1 with values of 0.08 or lower indicative of good fitting models. WRMR 
values of about 1.00 and lower are considered strong fits. 
 
Supplemental Tables S1 
Rotated Factor Matrices of the BNSS Exploratory Factor Analysis for One-Factor Solution (Item4 
Excluded) 
                1 
              ________ 
 BNSS1          0.854 
 BNSS2          0.840 
 BNSS3          0.843 
 BNSS5          0.805 
 BNSS6          0.774 
 BNSS7          0.855 
 BNSS8          0.822 
 BNSS9          0.891 
 BNSS10         0.899 
 BNSS11         0.895 
 BNSS12         0.795 
 BNSS13         0.817 
________________________________________________________________________________
_ 
Note. Loadings greater than 0.30 are presented in bold font. Quartimin rotation used. 
 Supplemental Table S2 
Rotated Factor Matrices of the BNSS Exploratory Factor Analysis for the Two-Factor Solution 
(Item4 Excluded) 
                 1             2 
              ________      ________ 
 BNSS1          0.952         0.031 
 BNSS2          1.041        -0.079 
 BNSS3          0.933         0.020 
 BNSS5          0.541         0.321 
 BNSS6          0.491         0.336 
 BNSS7          0.420         0.479 
 BNSS8          0.430         0.437 
 BNSS9         -0.007         0.960 
 BNSS10        -0.039         0.997 
 BNSS11        -0.027         0.976 
 BNSS12         0.037         0.807 
 BNSS13         0.114         0.757 
________________________________________________________________________________
_ 












Supplemental Table S3 
Rotated Factor Matrices of the BNSS Exploratory Factor Analysis for the Three-Factor Solution 
(Item4 Excluded) 
                1             2             3 
              ________      ________      ________ 
 BNSS1          1.013        -0.052         0.016 
 BNSS2          0.957         0.033        -0.011 
 BNSS3          0.850         0.091         0.029 
 BNSS5          0.238         0.588         0.074 
 BNSS6          0.147         0.682         0.039 
 BNSS7         -0.040         0.939         0.044 
 BNSS8         -0.023         0.968        -0.028 
 BNSS9          0.018        -0.053         0.992 
 BNSS10        -0.035         0.029         0.964 
 BNSS11        -0.040         0.039         0.951 
 BNSS12         0.011         0.026         0.808 
 BNSS13         0.095        -0.019         0.798 
________________________________________________________________________________
_ 













Supplemental Table S4 
Rotated Factor Matrices of the BNSS Exploratory Factor Analysis for the Four-Factor Solution 
(Item4 Excluded) 
                  1             2             3             4 
              ________      ________      ________      ________ 
 BNSS1          0.986        -0.020        -0.003         0.019 
 BNSS2          0.965         0.006        -0.009         0.021 
 BNSS3          0.860         0.060         0.083        -0.033 
 BNSS5          0.226         0.592        -0.068         0.126 
 BNSS6          0.140         0.697        -0.068         0.078 
 BNSS7         -0.022         0.881         0.080         0.025 
 BNSS8         -0.040         0.989         0.017        -0.035 
 BNSS9          0.040        -0.042        -0.014         0.975 
 BNSS10        -0.026         0.031         0.002         0.965 
 BNSS11        -0.012         0.035         0.057         0.886 
 BNSS12        -0.025         0.021         0.877         0.081 
 BNSS13         0.049         0.001         0.974        -0.029 
________________________________________________________________________________
_ 













Supplemental Table S5 
Rotated Factor Matrices of the BNSS Exploratory Factor Analysis for the Five-Factor Solution (Item4 Excluded) 
                 1             2             3             4             5 
              ________      ________      ________      ________      ________ 
 BNSS1          0.999        -0.007        -0.020         0.023        -0.015 
 BNSS2          0.980         0.008        -0.015         0.008        -0.003 
 BNSS3          0.903         0.001         0.050        -0.031         0.032 
 BNSS5          0.018         0.967        -0.021         0.015         0.030 
 BNSS6          0.065         0.540         0.316         0.046        -0.029 
 BNSS7          0.040         0.158         0.636         0.092         0.090 
 BNSS8          0.025        -0.018         0.972         0.011         0.011 
 BNSS9          0.034         0.039        -0.054         0.957        -0.011 
 BNSS10        -0.016        -0.010         0.037         0.974        -0.008 
 BNSS11         0.007        -0.022         0.039         0.894         0.051 
 BNSS12        -0.030         0.014         0.001         0.106         0.859 
 BNSS13         0.030         0.000         0.010        -0.051         1.010 
_________________________________________________________________________________ 
Note. Loadings greater than 0.30 are presented in bold font. Quartimin rotation used. 
 
 
  
  
  
 
 
 
  
  
  
  
 
